Business
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
There was plenty of clinical trial updates last week. Here’s a look.
Viatris executive chairman Robert Coury said that seeking new stewards for the site is the best route to ensure that people will have jobs and that the property would remain useful.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Aubrey de Grey has been accused by two women of predatory behavior, an allegation de Grey denies. SENS has placed him on administrative leave pending further investigation.
Republican Senator Rand Paul is under fire from government watchdogs for failing to properly disclose a $15,000 purchase of Gilead Sciences stock made by his wife last year.
Antheia has joined forces with Ginkgo Bioworks to strengthen its efforts in developing and producing essential medicines to treat a wide range of diseases.
Artiva Biotherapeutics is quadrupling its footprint in San Diego with a 52,000 square-foot corporate HQ, R&D and manufacturing center opening next year.
BioSpace recently spoke with James Oliviero, CEO and president at Checkpoint Therapeutics, an immuno-oncology, late-stage development company.
The global biopharmaceutical company said that it is well capitalized with cash, cash equivalents, restricted cash, and investments of as much as $222.8 million as of 30 June 2021.
The companies will harness the power of machine learning to increase the scalability of medicines based on spirulina, a type of blue-green algae.